NCT02234986Phase 2Completed

A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma

Study sponsor: CASI pharmaceuticals, Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2018-06-30Actual
Enrollment · participants35Actual
Source updated2025-04-18Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview